ASCLS eNewsBytes

• FDA approves new targeted therapy for NRG1 fusion-positive pancreatic cancer December 9, 2024
  The FDA has approved a drug targeting NRG1 gene fusion in 3% of pancreatic adenocarcinoma patients, highlighting the potential of precision medicine and the importance of biomarker testing and genetic testing for inherited mutations.
• Study shows education level, income impact access to stem cell transplantation for acute myeloid leukemia patients December 9, 2024
  A study from Fred Hutch Cancer Center found that patients with lower education and income are less likely to receive an allogeneic hematopoietic stem cell transplant for acute myeloid leukemia.
• Psilocybin therapy helps clinicians process COVID despair December 9, 2024
  A double-blind, randomized clinical trial found that psilocybin-assisted psychotherapy significantly reduced depression among clinicians providing front-line COVID-19 care in 2020 and 2021.
• Study claims AI could boost detection of breast cancer by 21% December 9, 2024
  A U.S. breast-screening program using artificial intelligence has shown a 21% increase in cancer detection rates for women who paid for AI-enhanced scans. The study, presented by DeepHealth, found overall cancer detection rates were 43% higher for those enrolled in the program.
• FDA approves durvalumab for limited-stage small cell lung cancer December 9, 2024
  The FDA has approved durvalumab for adults with limited stage small cell lung cancer without progression after platinum based chemotherapy and radiation therapy.